Deep Vein Thrombosis Latest News Archive
The Society of Radiologists in Ultrasound has endorsed recommendations regarding ultrasound imaging test protocols for patients with suspected deep venous thrombosis.
Surgical left atrial appendage occlusion is associated with a lower risk for thromboembolism-related hospital readmission in older patients with atrial fibrillation who undergo cardiac surgery.
Patients diagnosed with an intermediate-risk pulmonary embolism may be able to start oral anticoagulation therapy after completing 72 hours of heparin therapy during hospitalization.
The 10 mg dose of rivaroxaban substantially lowered the risk for recurrent venous thromboembolism.
Watching television frequently is independently associated with an increased risk for venous thromboembolism.
Venous thromboembolism risk does not increase with administration of the influenza vaccine in patients aged 50 years or older.
Novel oral anticoagulants lead to a one-fifth reduction in the risk of intraocular bleeding, compared with warfarin in patients with atrial fibrillation or venous thromboembolism.
Fondaparinux and rivaroxaban have higher efficacy of reducing venous thromboembolism after total hip or knee arthroplasty, but also an increased risk of major bleeding.
Hydroxychloroquine in combination with low-dose asprin was protective against thrombosis in SLE.
Patients who received 10 mg of rivaroxaban daily had decreased the rate of venous thromboembolism by 33%.
A meta-analysis was conducted to examine concerns surrounding direct oral anticoagulant therapy in patients with extreme high or low body weight.
A case study of a patient presented to the emergency room for right upper extremity deep vein thrombosis after rib resection and subclavian vein stent placement 15 years ago.
An increased risk of sepsis, venous thromboembolism and fracture was linked to short term use of oral corticosteroids.
Study results were contrary to investigators' hypothesis regarding warfarin dosing in patients with and without HIV.
Results from the EINSTEIN CHOICE trial plus an interview with investigator Philip Stephen Wells, MD, FRCP(C), MSc.
Pulmonary embolism risk after cerebral venous thromboembolism is significantly lower than after deep vein thromboembolism.
Patients with giant cell arteritis were more likely to experience venous thromboembolism during the first 3 months following diagnosis.
Two studies presented at CHEST 2016 revealed that rivaroxaban lowered the risk of venous thromboembolism without increasing risk of major bleeding.
Venous thromboembolism was only observed in patients with migraine with aura, suggesting a mechanistic link between the 2 conditions.
The Cardiology Advisor Articles
- Does Pre-Existing PH Affect Outcomes in Transcatheter Mitral Valve Repair?
- How Has the Medicaid Expansion Affected Patients Hospitalized With Acute MI?
- Macitentan Not Superior to Placebo for Improving Exercise Capacity in Eisenmenger Syndrome
- Occupational Metal, Pesticide Exposure May Be Associated With Increased CVD Risk
- FDA to Review Tafamidis for Treatment of Transthyretin Amyloid Cardiomyopathy
- ASH Develops Practice Guidelines for Venous Thromboembolism
- Tetralogy of Fallot: Long-Term Outcomes After Surgical Repair
- Stethoscopes in ICU Show High Levels of Bacterial Contamination
- Catheter Ablation Superior to Drug Therapy for Atrial Fibrillation in Heart Failure
- Trends in Endocarditis Incidence After Implementation of 2007 AHA Recommendations
- Researchers Identify Golden Ratio Between Pulmonary Pressure Components in PAH
- FDA: Potential Increased Mortality With Paclitaxel-Coated Balloons, Stents for PAD
- Inhaled Dry Powder Formulation of Treprostinil Well Tolerated in PAH
- Elevated Myocardial T1 Associated With Increased Septal Angle in PAH
- Pulmonary Hypertension Intensive Care Options Depend on Treatment Goals